The GSK-3 Inhibitor CT99021 Enhances the Acquisition of Spatial Learning and the Accuracy of Spatial Memory.
CT99021
DMTP T-maze
GSK-3
Morris water maze
NMDAR-dependent LTD
memory enhancement
spatial learning and memory
Journal
Frontiers in molecular neuroscience
ISSN: 1662-5099
Titre abrégé: Front Mol Neurosci
Pays: Switzerland
ID NLM: 101477914
Informations de publication
Date de publication:
2021
2021
Historique:
received:
28
10
2021
accepted:
30
12
2021
entrez:
14
2
2022
pubmed:
15
2
2022
medline:
15
2
2022
Statut:
epublish
Résumé
Glycogen synthase kinase 3 (GSK-3) is a Ser/Thr protein kinase that regulates many cellular processes, including synaptic plasticity. Previously, we reported that inhibition of GSK-3 prevents the induction of one of the major forms of synaptic plasticity, N-methyl-D-aspartate receptor (NMDAR)-dependent long-term depression (LTD), in hippocampal slices. In the present study, we have investigated the effects of inhibiting GSK-3 on learning and memory in healthy naïve animals. Systemic administration of a highly selective GSK-3 inhibitor, CT99021, reversibly blocked NMDAR-dependent LTD in the CA1 region of the hippocampus in anesthetized adult mice. In behavioral tasks, CT99021 had no effect on locomotor activity, anxiety, hippocampus-dependent contextual fear memory, and hippocampus-dependent reversal learning. However, CT99021 facilitated the rate of learning in the Morris water maze (MWM) and T-maze and enhanced the accuracy of long-term spatial memory in the MWM. These findings suggest that GSK-3 regulates the accuracy of spatial memory acquisition and recall.
Identifiants
pubmed: 35153671
doi: 10.3389/fnmol.2021.804130
pmc: PMC8829050
doi:
Types de publication
Journal Article
Langues
eng
Pagination
804130Informations de copyright
Copyright © 2022 Lee, Bortolotto, Bradley, Sanderson, Zhuo, Kaang and Collingridge.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Biochem J. 2007 Dec 15;408(3):297-315
pubmed: 17850214
Mol Brain. 2009 Jul 07;2:22
pubmed: 19583853
J Chem Neuroanat. 1999 Jun;16(4):279-93
pubmed: 10450875
Front Mol Neurosci. 2011 Aug 26;4:17
pubmed: 21904524
Eur J Neurosci. 2007 Jan;25(1):81-6
pubmed: 17241269
J Neurochem. 2003 Dec;87(6):1333-44
pubmed: 14713290
Front Mol Neurosci. 2014 May 21;7:46
pubmed: 24904272
Trends Neurosci. 2007 Mar;30(3):111-8
pubmed: 17234277
J Neurosci. 2013 Jul 17;33(29):12122-35
pubmed: 23864697
Front Mol Neurosci. 2012 Mar 15;5:33
pubmed: 22435049
Front Mol Neurosci. 2012 Feb 15;5:13
pubmed: 22363262
Neuropharmacology. 2013 Jan;64:65-73
pubmed: 22732443
Nat Rev Drug Discov. 2004 Jun;3(6):479-87
pubmed: 15173837
J Neurosci. 2012 May 23;32(21):7392-402
pubmed: 22623685
CRISPR J. 2020 Jun;3(3):198-210
pubmed: 32584144
Eur J Biochem. 1980 Jun;107(2):519-27
pubmed: 6249596
Philos Trans R Soc Lond B Biol Sci. 2013 Dec 02;369(1633):20130144
pubmed: 24298146
Eur J Neurosci. 2021 Oct;54(8):6815-6825
pubmed: 32463939
J Neurosci Methods. 2007 May 15;162(1-2):346-56
pubmed: 17306885
Cell Cycle. 2011 Jul 15;10(14):2255-62
pubmed: 21654194
Trends Biochem Sci. 2017 Mar;42(3):180-192
pubmed: 27876551
Expert Opin Ther Targets. 2018 Oct;22(10):833-848
pubmed: 30244615
Biol Psychiatry. 2011 Apr 15;69(8):748-53
pubmed: 21216393
Hippocampus. 2017 Aug;27(8):890-898
pubmed: 28556462
J Neurochem. 2008 Mar;104(6):1433-9
pubmed: 18088381
J Neuropathol Exp Neurol. 1999 Sep;58(9):1010-9
pubmed: 10499443
Nature. 2003 May 22;423(6938):435-9
pubmed: 12761548
Neurobiol Dis. 2009 Feb;33(2):193-206
pubmed: 19038340
Biol Psychiatry. 2014 Feb 1;75(3):198-206
pubmed: 24041505
PLoS One. 2015 Jul 24;10(7):e0134018
pubmed: 26207897
Behav Brain Res. 2017 Sep 29;335:122-127
pubmed: 28803855
Annu Rev Pharmacol Toxicol. 2009;49:327-47
pubmed: 18928402
PLoS One. 2010 Mar 16;5(3):e9706
pubmed: 20300527
Neuron. 2008 Apr 10;58(1):104-17
pubmed: 18400167
Neurobiol Dis. 2009 Aug;35(2):193-200
pubmed: 19379814
Proc Natl Acad Sci U S A. 2010 Sep 21;107(38):16697-702
pubmed: 20823230
J Pept Res. 1999 Jul;54(1):85-91
pubmed: 10448973
Schizophr Res. 2002 Nov 1;58(1):63-7
pubmed: 12363391
Neuron. 2007 Mar 1;53(5):703-17
pubmed: 17329210
Biochem Pharmacol. 2010 Feb 15;79(4):632-46
pubmed: 19799873
Front Behav Neurosci. 2015 Mar 04;9:55
pubmed: 25788881
J Neurosci. 2006 May 10;26(19):5083-90
pubmed: 16687499
J Clin Invest. 2013 Jan;123(1):224-35
pubmed: 23202730
Behav Neurosci. 1993 Aug;107(4):618-26
pubmed: 8397866
Sci Rep. 2019 Dec 2;9(1):18045
pubmed: 31792284
Neurobiol Dis. 2010 Aug;39(2):156-68
pubmed: 20381617
Sci Transl Med. 2020 May 20;12(544):
pubmed: 32434848
Neurochem Res. 2007 Apr-May;32(4-5):577-95
pubmed: 16944320
Neurobiol Dis. 2014 Jul;67:24-36
pubmed: 24636797
Nat Neurosci. 2011 May;14(5):545-7
pubmed: 21441921
Pharmacol Ther. 2014 Jan;141(1):1-12
pubmed: 23916593
J Neurosci. 1997 Apr 15;17(8):2921-7
pubmed: 9092613
Front Aging Neurosci. 2018 Jan 12;9:434
pubmed: 29375364
Eur Neuropsychopharmacol. 2002 Feb;12(1):13-25
pubmed: 11788236
Cells. 2020 Mar 16;9(3):
pubmed: 32188010
Clin Psychopharmacol Neurosci. 2017 May 31;15(2):100-114
pubmed: 28449557
EMBO J. 2021 Jan 15;40(2):e105513
pubmed: 33197065
Clin Transl Med. 2015 Mar 07;4:11
pubmed: 25852826
Learn Mem. 2013 Jun 14;20(7):352-7
pubmed: 23772089
Proc Natl Acad Sci U S A. 2004 Feb 17;101(7):2173-8
pubmed: 14769913
Trends Immunol. 2010 Jan;31(1):24-31
pubmed: 19836308
J Neurosci. 2007 Feb 21;27(8):1981-91
pubmed: 17314294
J Hum Genet. 2017 Jun;62(6):589-597
pubmed: 28228639
J Neuropathol Exp Neurol. 1997 Jan;56(1):70-8
pubmed: 8990130
Front Mol Neurosci. 2011 Aug 09;4:16
pubmed: 21886606
J Neurosci. 2015 Mar 25;35(12):4804-12
pubmed: 25810511
Nature. 1997 May 29;387(6632):497-500
pubmed: 9168111
PLoS Med. 2007 May;4(5):e182
pubmed: 17535104
Neurobiol Dis. 2010 Mar;37(3):622-9
pubmed: 20004245
Sci Rep. 2017 Jul 18;7(1):5781
pubmed: 28720858
Science. 1998 Sep 25;281(5385):2038-42
pubmed: 9748165
J Neurosci. 2009 Jul 8;29(27):8633-8
pubmed: 19587269
Eur J Biochem. 1983 Jan 17;130(1):227-34
pubmed: 6402364
Neuropharmacology. 2013 Jan;64:205-14
pubmed: 22749842
Cell Death Differ. 2002 Dec;9(12):1294-306
pubmed: 12478466
J Neurosci. 1993 Sep;13(9):3916-25
pubmed: 8366351
J Neurochem. 2002 Dec;83(6):1529-33
pubmed: 12472906
Neuropsychopharmacology. 2011 Jun;36(7):1397-411
pubmed: 21389981
Neuron. 2016 Mar 2;89(5):1100-9
pubmed: 26898776
PLoS Biol. 2004 Aug;2(8):E225
pubmed: 15314651
Neuron. 2009 Jun 25;62(6):788-801
pubmed: 19555648
Front Mol Neurosci. 2011 Nov 01;4:35
pubmed: 22053151
Nature. 1986 Feb 27-Mar 5;319(6056):774-6
pubmed: 2869411
Hippocampus. 2014 Dec;24(12):1413-6
pubmed: 25208523
Front Mol Neurosci. 2017 Sep 20;10:295
pubmed: 28979184
J Neurochem. 2011 Dec;119(6):1330-40
pubmed: 21992552
Nat Neurosci. 2011 Oct 23;14(11):1447-54
pubmed: 22019731
PLoS One. 2014 Feb 04;9(2):e88026
pubmed: 24505362